Gilead Announces Positive Data From Phase 3 Tropics-02 Study Of Trodelvy Versus Comparator Chemotherapies In Patients With Hr+/Her2- Metastatic Breast Cancer

Gilead Sciences, Inc. Announced New Data From A Post Hoc Subgroup Analysis From The Phase 3 Tropics-02 Study Evaluating Trodelvy (Sacituzumab Govitecan-Hziy) Versus Comparator Chemotherapies (Physicians